RxDoctor Payments Data

Kenneth Lan, MD

Internal Medicine · Kansas City, MONPI 1316439169

Payments from drug & device makers

$3,975in general payments, 2019–2025

Across 226 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$625
  • AstraZeneca$584
  • AbbVie$488
  • Novo Nordisk$447
  • Amgen$265
  • Pfizer$212
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$3,90398%
  • Education$722%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,975 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$37,634
Medicare patients
160
Services billed
808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$127,458
JardianceEmpagliflozin97$123,224
MounjaroTirzepatide93$106,254
EliquisApixaban51$77,704
RybelsusSemaglutide34$46,604
FarxigaDapagliflozin Propanediol33$36,594
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$30,795
XareltoRivaroxaban22$25,784
Repatha SureclickEvolocumab18$23,157
JanuviaSitagliptin Phosphate18$18,091
TrulicityDulaglutide12$17,219
BelsomraSuvorexant32$15,136
SymbicortBudesonide/Formoterol Fumarate22$12,294
LinzessLinaclotide13$11,483
ArexvyRsvpref3 Antigen/As01e/Pf32$8,440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$447$174,062140 claims
Lilly USA, LLCMounjaro, Trulicity$625$123,473105 claims
Boehringer IngelheimJardiance$212$123,22497 claims
PfizerEliquis$212$77,70451 claims
AstraZenecaFarxiga, Symbicort$584$48,88855 claims
GSKTrelegy Ellipta, Arexvy, Arnuity Ellipta$91$44,17779 claims
MerckJanuvia, Belsomra, Janumet Xr$123$39,42561 claims
Johnson & JohnsonXarelto$76$25,78422 claims
AbbVieLinzess, Creon$488$16,44525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →